Computational Modeling and Pharmacokinetics/ADMET Study of Some Arylpiperazine Derivatives as Novel Antipsychotic Agents Targeting Depression

2020 ◽  
Vol 3 (4) ◽  
pp. 979-988 ◽  
Author(s):  
Sabitu Babatunde Olasupo ◽  
Adamu Uzairu ◽  
Gideon Shallangwa Adamu ◽  
Sani Uba
Keyword(s):  
Computational Modeling ◽  
Antipsychotic Agents ◽  
Novel Antipsychotic

Development of novel antipsychotic agents by inhibiting dopamine transporter – in silico approach

2022 ◽  
Author(s):  
Vladimir Đorđević ◽  
Srđan Pešić ◽  
Jelena Vladeta Zivkovic ◽  
Goran M Nikolić ◽  
Aleksandar M Veselinović
Keyword(s):  
Dopamine Transporter ◽  
In Silico ◽  
Treatment Approach ◽  
Antipsychotic Agents ◽  
Research Paper ◽  
Qsar Modeling ◽  
Novel Antipsychotic

Dopamine transporter inhibition is deemed a promising schizophrenia treatment approach. This research paper outlines various QSAR modeling for molecules acting as dopamine transporter inhibitors. The SMILES notation and the local...

Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia

2003 ◽  
Vol 13 (4) ◽  
pp. 425-448 ◽  
Author(s):  
Stefania Butini ◽  
Giuseppe Campiani ◽  
Meri De Angelis ◽  
Caterina Fattorusso ◽  
Vito Nacci ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Antipsychotic Agents ◽  
Recent Advances ◽  
Novel Antipsychotic

Tardive Dyskinesia: A Review

1995 ◽  
Vol 40 (7_suppl) ◽  
pp. 49-54 ◽  
Author(s):  
Paul R Latimer
Keyword(s):  
Clinical Practice ◽  
Tardive Dyskinesia ◽  
Antipsychotic Agent ◽  
Antipsychotic Agents ◽  
The Elderly ◽  
Research Findings ◽  
Chronic Neuroleptic ◽  
Novel Antipsychotic ◽  
Iatrogenic Disorder ◽  
Typical Neuroleptics

Objective: To review recent research findings on tardive dyskinesia (TD) with relevance to clinical practice. Method: TD is a syndrome of involuntary movements that can occur in association with chronic neuroleptic use. It is of unknown pathophysiology. It can be irreversible, is cosmetically disfiguring, and can be functionally disabling. Results: There is as yet no treatment of demonstrated efficacy for TD. It is an iatrogenic disorder whose incidence is increased by age and total cumulative dose of typical neuroleptics. It has been the source of successful litigation in some jurisdictions but, until very recently, there has been no effective antipsychotic agent without this effect. Conclusion: This litigation in some jurisdictions has been a major impetus to the development of novel antipsychotic agents. It is less well known that a similar, possibly identical, movement disorder occurs spontaneously particularly in the elderly and inpatients with schizophrenia, and that TD is often reversible.

Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents

2000 ◽  
Vol 41 (1) ◽  
pp. 38-39
Author(s):  
S.R. David ◽  
K.M. Meehan ◽  
V.K. Sutton ◽  
C.C. Taylor
Keyword(s):  
Negative Symptoms ◽  
Antipsychotic Agents ◽  
Novel Antipsychotic
Sign in / Sign up

Export Citation Format

Share Document